Patents by Inventor Yi Xing

Yi Xing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240128616
    Abstract: A battery pack, comprising a first cell and a second cell connected in series, the first cell having a current cut-off device and having a first failure voltage, the current cut-off device being configured to be able to break a circuit in response to a voltage value of the first cell reaching or exceeding the first failure voltage, and the second cell having no current cut-off device. The battery pack may use a soft pack battery as the second cell, having advantages such as high energy density, low impedance, high discharge power, a low rate of temperature rise during high-rate discharge, and flexibility in dimensions.
    Type: Application
    Filed: September 29, 2023
    Publication date: April 18, 2024
    Inventors: Yi ZHANG, Yun Yan JIA, Si Xing ZHOU, Jia Wei CHEN
  • Publication number: 20240076496
    Abstract: The present invention provides a thermally conductive silicone composition comprising: (A) at least one alkenyl group-containing organopolysiloxane; (B) at least one organohydrogenpolysiloxane having at least two hydrogen atoms directly bonded to a silicon atom in the molecule; (C1) one or more silane surface-treated alumina particles having a D50 particle size of at least 0.01 ?m but no greater than 5 ?m; (C2) one or more silane surface-treated alumina particles having a D50 particle size of greater than 5 ?m; (D) at least one silane coupling agent; and (E) at least one platinum-based curing catalyst; wherein component (C1) is present in an amount of less than 62% by weight based on the weight of the composition and the component (C2) is present in an amount of less than 80% by weight based on the weight of the composition, which features favorable combination of properties including good flowability, as well as high thermal conductivity and good lap shear strength when cured.
    Type: Application
    Filed: November 9, 2023
    Publication date: March 7, 2024
    Inventors: Wentao Xing, Yi Liu, Xiaolong Hu
  • Publication number: 20240071626
    Abstract: Embodiments of the present disclosure relate to automated validation of medical data. Some embodiments of the present disclosure provide a method for medical data validation. The method comprises obtaining target medical data generated in a medical test and obtaining a machine learning model for validating medical data. The machine learning model represents an association between the medical data and validation results, the validation results indicating information about predetermined actions to be performed on the medical data. The method further comprises determining a target validation result for the target medical data by applying the target medical data to the machine learning model, the target validation result indicating information about a target action selected from the predetermined actions to be performed on the target medical data. Through the solution, it is possible to achieve automated medical data validation with high accuracy and efficiency as well as reduced manual efforts.
    Type: Application
    Filed: August 26, 2022
    Publication date: February 29, 2024
    Applicants: Roche Diagnostics Operations, Inc., Qilu Hospital of Shandong University
    Inventors: Daquan Liu, Yin Qian, Xiaojun Tao, Hongchun Wang, Weibin Xing, Chenxi Zhang, Yi Zhang, Qi Zhou
  • Publication number: 20230027985
    Abstract: The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.
    Type: Application
    Filed: November 12, 2020
    Publication date: January 26, 2023
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc.
    Inventors: Daniel MEIBOM, Yolanda CANCHO GRANDE, Pierre WASNAIRE, Sarah Anna Liesa JOHANNES, Niels LINDNER, Kristin BEYER, Till FREUDENBERGER, Damian BROCKSCHNIEDER, Ilka MATHAR, Jürgen KLAR, Dmitry ZUBOV, Dzianis MENSHYKAU, Tanja KRAINZ, Eric STEFAN, Bryan MACDONALD, Yi XING, Nadine ELOWE, Guzman SANCHEZ
  • Publication number: 20230027346
    Abstract: The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.
    Type: Application
    Filed: November 12, 2020
    Publication date: January 26, 2023
    Applicants: BAYER AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC.
    Inventors: Daniel MEIBOM, Yolanda CANCHO GRANDE, Pierre WASNAIRE, Sarah Anna Liesa JOHANNES, Kristin BEYER, Till FREUDENBERGER, Damian BROCKSCHNIEDER, Dmitry ZUBOV, Dzianis MENSHYKAU, Tanja KRAINZ, Bryan MACDONALD, Yi XING, Nadine ELOWE, Guzman SANCHEZ
  • Publication number: 20220412975
    Abstract: Provided herein are assays for the detection and characterization of modulators of ADAMTS-7 and/or ADAMTS-12. Also provided herein are recombinant nucleic acids for the improved expression of functional metalloproteinases ADAMTS-7 and nucleic acids for the improved expression of functional metalloproteinases ADAMTS-12. In addition, provided herein are peptide substrates (e.g. FRET substrates) for use in assays for the detection and characterization of modulators of ADAMTS-7 and/or ADAMTS-12.
    Type: Application
    Filed: November 12, 2020
    Publication date: December 29, 2022
    Inventors: Dmitry Zubov, Bryan MacDonald, Yi Xing, Nadine Elowe, Damian Brockschnieder
  • Patent number: 11520997
    Abstract: A device and a method for generating a machine translation model and a machine translation device are disclosed. The device inputs a source training sentence of a source language and a dictionary data to a generator network so that the generator network outputs a target training sentence of a target language according to the source training sentence and the dictionary data. Then, the device inputs the target training sentence and a correct translation of the source training sentence to a discriminator network so as to calculate an error between the target training sentence and the correct translation according to the output of the discriminator network, and trains the generator network and the discriminator network respectively. The trained generator network is the machine translation model.
    Type: Grant
    Filed: November 29, 2019
    Date of Patent: December 6, 2022
    Assignee: National Central University
    Inventors: Jia-Ching Wang, Yi-Xing Lin
  • Publication number: 20220380937
    Abstract: Methods and processes to identify neoplastic tissue antigens derived from alternative splicing (AS) are described, in accordance with various embodiments of the invention. Also described are novel tumor antigens that are useful as targets in various immunotherapeutic approaches to treating brain cancer as well as novel engineered T cell Receptors (TCRs) and chimeric antigen receptors (CARs) that target these antigenic peptides.
    Type: Application
    Filed: November 6, 2020
    Publication date: December 1, 2022
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Yi XING, Robert PRINS, Yang PAN, Alexander H. LEE
  • Patent number: 11286192
    Abstract: The present invention discloses a high-moisture sludge ultra-fine synchronizing deep-drying device and a method thereof. The device has a sludge ultrafine pulverizing unit and a sludge drying unit arranged horizontally in parallel, and a pulverized sludge discharge port arranged between them. The sludge ultrafine pulverizing unit comprises a sludge pulverizing chamber and a sludge feeding port, and the sludge pulverizing chamber is a hollow cylindrical structure with a pulverizing rotation shaft arranged in the center, and the pulverizing rotation shaft is provided with a sludge pulverizing impeller. The lower part of the sludge feeding port is provided with a first baffle and/or a second deflector. The sludge is pulverized into sludge powders in the sludge pulverizing chamber, and then fed into the sludge drying chamber to be fluidized and dried. The present invention has the advantage of high drying efficiency, etc.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: March 29, 2022
    Assignees: University of Science and Technology Beijing, Shengshi Weilan (Shandong) Envi Sci & Tech Co Ltd
    Inventors: Yi Xing, Chen Hong, Yanxiao Si, Wei Su, Bo Jiang
  • Publication number: 20210157991
    Abstract: A device and a method for generating a machine translation model and a machine translation device are disclosed. The device inputs a source training sentence of a source language and a dictionary data to a generator network so that the generator network outputs a target training sentence of a target language according to the source training sentence and the dictionary data. Then, the device inputs the target training sentence and a correct translation of the source training sentence to a discriminator network so as to calculate an error between the target training sentence and the correct translation according to the output of the discriminator network, and trains the generator network and the discriminator network respectively. The trained generator network is the machine translation model.
    Type: Application
    Filed: November 29, 2019
    Publication date: May 27, 2021
    Inventors: Jia-Ching WANG, Yi-Xing LIN
  • Publication number: 20200308039
    Abstract: The present invention discloses a high-moisture sludge ultra-fine synchronizing deep-drying device and a method thereof. The device has a sludge ultrafine pulverizing unit and a sludge drying unit arranged horizontally in parallel, and a pulverized sludge discharge port arranged between them. The sludge ultrafine pulverizing unit comprises a sludge pulverizing chamber and a sludge feeding port, and the sludge pulverizing chamber is a hollow cylindrical structure with a pulverizing rotation shaft arranged in the center, and the pulverizing rotation shaft is provided with a sludge pulverizing impeller. The lower part of the sludge feeding port is provided with a first baffle and/or a second deflector. The sludge is pulverized into sludge powders in the sludge pulverizing chamber, and then fed into the sludge drying chamber to be fluidized and dried. The present invention has the advantage of high drying efficiency, etc.
    Type: Application
    Filed: March 19, 2020
    Publication date: October 1, 2020
    Inventors: Yi XING, Chen HONG, Yanxiao SI, Wei SU, Bo JIANG
  • Publication number: 20190276498
    Abstract: The disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins. The modified gL proteins remain intact and are able to form complexes with other CMV proteins.
    Type: Application
    Filed: November 15, 2018
    Publication date: September 12, 2019
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventors: Andrea CARFI, Claudio CIFERRI, Yi XING
  • Patent number: 10167321
    Abstract: This disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins. The modified gL proteins remain intact and are able to form complexes with other CMV proteins.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: January 1, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Andrea Carfi, Claudio Ciferri, Yi Xing
  • Patent number: 9999571
    Abstract: A uniform-distribution filling mechanism for medicinal powder includes a metering disk, a powder storage ring, and a lateral powder blocker. One end of the blocker is provided with a pointed tip, and the other end thereof is provided with a sloping stage. The middle portion of the metering disk is provided with a support shaft, said shaft and the blocker being connected one to the other by means of a support arm. Medicinal powder enters via the pointed tip of the blocker, is evenly agitated, exits via the sloping stage of the blocker, and is evenly dispensed. Thus, the powder is able to enter one side of the blocker and come out the other side thereof such that the powder is evenly dispensed and then uniformly distributed onto the metering disk.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: June 19, 2018
    Assignee: ZHEJIANG HUASHILI MACHINERY CO., LTD.
    Inventors: Jin Jin Ding, Jie Su, Jun Yong Ying, Hong Su, Jun Guo Li, Xu Zhan Chen, Yi Xing Huang
  • Publication number: 20170369532
    Abstract: This disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins. The modified gL proteins remain intact and are able to form complexes with other CMV proteins.
    Type: Application
    Filed: January 22, 2016
    Publication date: December 28, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Andrea CARFI, Claudio CIFERRI, Yi XING
  • Publication number: 20160264934
    Abstract: The present invention generally relates to methods, assays and kits to maintain a human stem cell population in an undifferentiated state by inhibiting the expression or function of METTL3 and/or METTL4, and m6A fingerprint methods, assays, arrays and kits to assess the cell state of a human stem cell population by assessing m6A levels (e.g. m6A peak intensities) of a set of target genes disclosed herein to determine if the stem cell is in an undifferentiated or differentiated state.
    Type: Application
    Filed: March 11, 2016
    Publication date: September 15, 2016
    Applicants: THE GENERAL HOSPITAL CORPORATION, The Regents of the University of California
    Inventors: Cosmas GIALLOURAKIS, Alan C. MULLEN, Yi XING
  • Publication number: 20160256354
    Abstract: A uniform-distribution filling mechanism for medicinal powder includes a metering disk, a powder storage ring, and a lateral powder blocker. One end of the blocker is provided with a pointed tip, and the other end thereof is provided with a sloping stage. The middle portion of the metering disk is provided with a support shaft, said shaft and the blocker being connected one to the other by means of a support arm. Medicinal powder enters via the pointed tip of the blocker, is evenly agitated, exits via the sloping stage of the blocker, and is evenly dispensed. Thus, the powder is able to enter one side of the blocker and come out the other side thereof such that the powder is evenly dispensed and then uniformly distributed onto the metering disk.
    Type: Application
    Filed: October 17, 2014
    Publication date: September 8, 2016
    Applicant: ZHEJIANG HUASHILI MACHINERY CO., LTD.
    Inventors: Jin Jin DING, Jie SU, Jun Yong YING, Hong SU, Jun Guo LI, Xu Zhan CHEN, Yi Xing HUANG
  • Publication number: 20150045410
    Abstract: The present invention relates to therapeutic agents comprising miR-138, a miR-138 mimic, a SIN3A RNAi molecule, or a an anti-SIN3A RNAi molecule, and/or an anti-SIN3A antisense oligonucleotide (ASO) or other agent that suppresses SIN3A expression, a small molecule drug that interferes with SIN3A activity or whose actions mimic the biological effects of SIN3A suppression and methods of use of these therapeutic agents to treat cystic fibrosis.
    Type: Application
    Filed: February 6, 2013
    Publication date: February 12, 2015
    Inventors: Paul McCray, Shyam Ramachandran, Yi Xing, Michael Welsh, Mark Behlke
  • Publication number: 20060250787
    Abstract: A pointer pen which is disclosed includes a rechargeable battery, a switch, a light-emitting element, and an interface unit including a voltage transforming and charging circuit and a USB connecter. The USB connector may be plugged into a USB port of a device (e.g., laptop computer) when the battery run down. Thereafter, an external power is supplied to the voltage transforming and charging circuit for voltage transformation through the connection between the USB connector and the USB port. The transformed voltage is then supplied to the battery for charging. The pointer pen has a prolonged operating time and is capable for being charged quickly in a convenient way when its battery runs down while a lecture is given.
    Type: Application
    Filed: May 5, 2006
    Publication date: November 9, 2006
    Applicant: Inventec Appliances Corp.
    Inventors: David Ho, Yi Xing